2017_SBRT_Course Book

Neurocognitive decline after WBRT

Reference

Patients

Dose PCI

Baseline Abnormalities (free) Control: 44% PCI: 50%

Cognitive impairment after a year

Arrigada

294; SCLC

24 Gy

Control:36% PCI: 30% Control: 17% PCI:31%

Gregor

314; SCLC

8-36Gy

PASAT

Wolfson

264; SCLC

25 vs 36Gy

25Gy: 62% 36Gy: 85% 25Gy :35% 36Gy: 47%

Le Pechoux

720; SCLC

25 vs 36Gy

Sun

340; SCLC Control:12% PCI: 41% • At least one neurocognitve dysfunction could be observed after WBRT • Grade of impairment depends of the dose 30Gy